Actively personalized vaccination trial for newly diagnosed glioblastoma
2018 · Nature · 897 citations
https://doi.org/10.1038/s41586-018-0810-y
N
Norbert Hilf
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
163
Papers
4.4K
Citations
22
h-index
29
i10-index
Norbert Hilf is an academic researcher from Immatics Biotechnologies (Germany). The author has contributed to research in topics: CAR-T cell therapy research & Cancer Research and Treatments & Immunotherapy and Immune Responses. The author has an h-index of 22, co-authored 139 publications.
ORCID: 0000-0002-2618-8174Papers by this author
worksIdentification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma
2019 · Molecular & Cellular Proteomics · 66 citations
https://doi.org/10.1074/mcp.ra119.001524
Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial
2025 · Nature Medicine · 29 citations
https://doi.org/10.1038/s41591-025-03650-6
Supplemental Figure 3 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · 0 citations
https://doi.org/10.1158/2326-6066.27026573
Supplemental Figure 2 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · 0 citations
https://doi.org/10.1158/2326-6066.27026576
Supplemental Figure 4 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
2024 · 0 citations
https://doi.org/10.1158/2326-6066.27026570.v1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat